Evaluation of the Inhibitory Effects of (E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one (DiNap), a Natural Product Analog, on the Replication of Type 2 PRRSV In Vitro and In Vivo

• Published in: Molecules (Basel, Switzerland) Switzerland), 2019-03, Vol.24 (5), p.887
• Main Authors: Khatun, Amina, Park, Sun You, Shabir, Nadeem, Nazki, Salik, Kang, A-Rum, Jeong, Chang-Gi, Seo, Byoung-Joo, Yang, Myeon-Sik, Kim, Bumseok, Seo, Young Ho, Kim, Won-Il
• Format: Article
• Language: English
• Subjects: Alveoli; Animal diseases; antiviral therapeutics; Biocompatibility; Cell lines; Cytotoxicity; DiNap; Evaluation; Genomes; Hogs; Infections; Infectious diseases; Lungs; Macrophages; Natural products; pigs; Potassium; PRRSV; Replication; Swine; Vaccines; Viral infections; Viruses; VR2332
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules24050887

DiNap [( )-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one], an analog of a natural product (the chalcone flavokawain), was synthesized and characterized in this study. Porcine reproductive and respiratory syndrome virus (PRRSV) is the most challenging threat to the swine industry worldwide. Currently, commercially available vaccines are ineffective for controlling porcine reproductive and respiratory syndrome (PRRS) in pigs. Therefore, a pharmacological intervention may represent an alternative control measure for PRRSV infection. Hence, the present study evaluated the effects of DiNap on the replication of VR2332 (a prototype strain of type 2 PRRSV). Initially, in vitro antiviral assays against VR2332 were performed in MARC-145 cells and porcine alveolar macrophages (PAMs). Following this, a pilot study was conducted in a pig model to demonstrate the effects of DiNap following VR2332 infection. DiNap inhibited VR2332 replication in both cell lines in a dose-dependent manner, and viral growth was completely suppressed at concentrations ≥0.06 mM, without significant cytotoxicity. Consistent with these findings, in the pig study, DiNap also reduced viral loads in the serum and lungs and enhanced the weight gain of pigs following VR2332 infection, as indicated by comparison of the DiNap-treated groups to the untreated control (NC) group. In addition, DiNap-treated pigs had fewer gross and microscopic lesions in their lungs than NC pigs. Notably, virus transmission was also delayed by approximately 1 week in uninfected contact pigs within the same group after treatment with DiNap. Taken together, these results suggest that DiNap has potential anti-PRRSV activity and could be useful as a prophylactic or post-exposure treatment drug to control PRRSV infection in pigs.